TKIs are effective against cancers that have specific genetic mutations leading to the overactivation of tyrosine kinases. For instance, chronic myeloid leukemia (CML) is often caused by the BCR-ABL fusion gene, which results in the production of an abnormal tyrosine kinase. TKIs like imatinib can specifically inhibit this abnormal enzyme, thus controlling the disease.
